scholarly journals Follicular Variant of Papillary Thyroid Carcinoma on the Basis of His-topathological and Immunohistochemical Diagnosis

2017 ◽  
Vol 42 (1) ◽  
pp. 21-27
Author(s):  
Mohammad Mosiur Rahman ◽  
Sultana Gulshan Banu ◽  
Ashim Ranjan Barua ◽  
Mohammed Kamal ◽  
Muhammod Nazmul Baqui ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Diagnostic Accuracy ◽  
Papillary Carcinoma ◽  
Follicular Adenoma ◽  
Minor Component ◽  
Follicular Carcinoma ◽  
Papillary Thyroid ◽  
Medical Surveillance ◽  
Follicular Variant

A significant increase in incidence of papillary thyroid carcinoma (PTC) has been noticed in recent decades worldwide. This is due to advances in medical surveillance, increased use of ancillary tests, and a minor component due to over diagnosis of PTC. Follicular variant of papillary thyroid carcinoma (FVPTC) is the second most common variant of PTC and comprises about 23-41%. It is difficult to diagnose histologically when the distinctive nuclear features are either not well developed or present focally within the lesion. Several immunohistochemical markers (CD56, HMCK, GAL3, HBME-1 and CK19) either alone or combined in panels can be used to improve diagnostic accuracy. This study was aimed to differentiate FVPTC from other follicular patterned lesion of thyroid by histopathology and immunohistochemistry (IHC). A total of 50 histologically diagnosed cases of thyroid neoplasm were studied. The neoplastic cases included 40 cases of follicular variant papillary carcinoma (FVPC), 04 classic papillary carcinoma (PTC), 04 follicular carcinoma and 02 follicular adenoma. All cases were evaluated by IHC for the expression of CD56 and CK19 antibody. In case of FVPTC (n=40), 21 cases (52.5%) were CK19 positive and CD56 negative as expected. Both markers were found positive in 06 (15%) cases and CD56+ alone was found positive in 11 (27.5%) cases of FVPTC, and a finding that goes against the diagnosis of FVPTC. The histopathological slides of these cases were reviewed and findings were recorded. All cases (n=4) of classic PTC were CK19 positive and 03 (75%) cases were found CD56 negative. Diagnoses of thyroid follicular lesions are primarily based on histological and cytomorphological criteria. However, there was a subset of follicular patterned tumors like FVPTC which lack unequivocal features of malignancy. Immunohistochemistry can improve diagnostic accuracy but needs additional studies for controversial cases. It may be considered these lesions as differentiated tumor of uncertain malignant potential (WDT-UMP) to avoid the using term carcinoma. Additional studies are needed for establishing more precise morphologic criteria and for identifying useful markers for differentiating benign from borderline or malignant thyroid lesions.

scholarly journals Diagnostic value of CD56 immunohistochemistry in thyroid lesions

2018 ◽  
Vol 33 (2) ◽  
pp. 161-167 ◽  
Author(s):  
Jung-Soo Pyo ◽  
Dong-Hoon Kim ◽  
Jungho Yang
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Hashimoto’S Thyroiditis ◽  
Follicular Adenoma ◽  
Follicular Carcinoma ◽  
Hashimoto's Thyroiditis ◽  
Papillary Thyroid ◽  
Follicular Variant ◽  
Cd56 Expression ◽  
Thyroid Lesions

Purpose: The present study aimed to evaluate the diagnostic roles of CD56 immunohistochemistry in differentiating various thyroid lesions. Methods: A meta-analysis was performed to evaluate the rate of loss of CD56 immunohistochemistry expression from 13 eligible studies regarding various thyroid lesions, including papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma. To confirm the value of CD56 immunohistochemistry in differentiating various thyroid lesions, a diagnostic test accuracy review was conducted. Results: An 87.8%, 79.1%, 11.9%, 25.5%, and 19.6% loss of CD56 immunohistochemistry expression was identified in papillary thyroid carcinoma, follicular carcinoma, follicular adenoma, benign follicular nodule, and Hashimoto’s thyroiditis, respectively. In the normal thyroid tissue, the rate of loss of CD56 expression was 1.6%. Classical, follicular, diffuse sclerosing, tall cell, and encapsulated variants of papillary thyroid carcinoma showed an 88.4%, 75.3%, 97.2%, 91.7%, and 91.7% loss of CD56 expression, respectively. In the comparison between the follicular variant of papillary thyroid carcinoma and follicular adenoma, the pooled sensitivity and specificity of CD56 immunohistochemistry was 0.82 (95% confidence interval (CI) 0.70, 0.90) and 0.94 (95% CI 0.83, 0.99), respectively. The diagnostic odds ratio and the area under curve on summary receiver operating characteristic curve was 51.43 (95% CI 5.83, 453.88) and 0.9387, respectively. Conclusion: Collectively, these results indicate that the rate of loss of CD56 immunohistochemistry expression was significantly higher in malignant tumors, such as papillary thyroid carcinoma and follicular carcinoma, than in follicular adenoma, benign follicular nodule, and Hashimoto’s thyroiditis. As such, CD56 immunohistochemistry can be useful in differentiating follicular variant papillary thyroid carcinoma from follicular adenoma.

BRAFK601E Mutation in a Follicular Thyroid Adenoma: A Case Report

2017 ◽  
Vol 25 (4) ◽  
pp. 348-351 ◽  
Author(s):  
Elisabetta Macerola ◽  
Liborio Torregrossa ◽  
Clara Ugolini ◽  
Sohail Bakkar ◽  
Paolo Vitti ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Treatment Plan ◽  
Follicular Adenoma ◽  
Surrounding Tissue ◽  
Papillary Thyroid ◽  
Follicular Variant ◽  
Thyroid Lesion ◽  
Cytological Smear ◽  
Benign Thyroid

BRAF mutations represent the most common genetic alteration in papillary thyroid carcinoma (PTC). The p.V600E mutation is specific for the classic and tall-cell variants of PTC and has been associated with a more aggressive biologic behavior. On the other hand, the p.K601E mutation is peculiar to the follicular variant of PTC, and seems to be a favorable prognostic indicator. A 12-year-old boy presented with a 10-mm left-sided thyroid nodule. Fine-needle aspiration cytology reported the lesion as suspicious for a follicular neoplasm (Bethesda category IV). The patient underwent lobectomy, and histopathology revealed a follicular adenoma with normal surrounding tissue. The cytological smear was found to be positive for BRAF p.K601E mutation, and this was later confirmed on the corresponding paraffin block. This case was independently revised by 4 expert pathologists, all of whom confirmed the benign nature of the thyroid lesion. This article describes the presence of a BRAF mutation in a benign thyroid lesion. To the authors’ knowledge, this is the fourth case of follicular adenoma carrying BRAFK601E reported in literature to date. BRAFK601E mutation can occur in benign thyroid lesions. This finding, in the context of the current literature and the recently proposed reclassification of the noninvasive encapsulated follicular variant of papillary thyroid carcinoma into a benign lesion, confirms the importance of preoperative BRAF p.K601E testing in offering patients a tailored treatment plan and avoiding overtreatment.

Immunohistochemical Separation of Follicular Variant of Papillary Thyroid Carcinoma from Follicular Adenoma

2006 ◽  
Vol 17 (3) ◽  
pp. 213-224 ◽  
Author(s):  
Nobuki Nakamura ◽  
Lori A. Erickson ◽  
Long Jin ◽  
Sabine Kajita ◽  
Heyu Zhang ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Follicular Adenoma ◽  
Papillary Thyroid ◽  
Follicular Variant

The use of fluorescence lifetime technology in benign and malignant thyroid tissues

2019 ◽  
Vol 133 (8) ◽  
pp. 696-699
Author(s):  
G Nakache ◽  
G Yahav ◽  
G H Siloni ◽  
I Barshack ◽  
E Alon ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Fluorescence Lifetime ◽  
Follicular Adenoma ◽  
Follicular Carcinoma ◽  
Fluorescein Isothiocyanate ◽  
Fluorescence Lifetime Imaging ◽  
Papillary Thyroid ◽  
Lifetime Measurements ◽  
Fresh Frozen

AbstractObjectiveTo explore the use of fluorescence lifetime imaging microscopy in thyroid tissues, and to investigate how different thyroid lesions affect fluorescence lifetime.MethodFluorescence lifetime measurements were taken of fresh frozen thyroid surgical specimens stained with fluorescein isothiocyanate tagged anti-thyroglobulin monoclonal antibodies.ResultsThe mean fluorescence lifetime measurements in 12 patients – 3 with multinodular goitre, 4 with follicular adenoma, 4 with papillary thyroid carcinoma and 1 with follicular carcinoma – were 3.16 ns (range, 2.66–3.52 ns), 3.75 ns (range, 2.99–4.57 ns), 2.97 ns (range, 2.57–3.21 ns) and 3.61 ns, respectively. The fluorescence lifetime of follicular adenoma patients was higher than that of papillary thyroid carcinoma patients by 26 per cent (p = 0.058). The fluorescence lifetime in the follicular carcinoma patient was similar to the follicular adenoma group, but higher than in the papillary thyroid carcinoma group by 22 per cent (p = 0.01).ConclusionFluorescence lifetime measurements varied in different thyroid pathologies, possibly because of tissue-scale structural influences.

scholarly journals Lindsay tumor: An unusual entity: A case study with review of literature

2016 ◽  
Vol 02 (01) ◽  
pp. 043-045
Author(s):  
Yasmin Momin ◽  
Sameer Ansari ◽  
Bharat Ghodke
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Rare Case ◽  
Follicular Carcinoma ◽  
Hematogenous Metastasis ◽  
Papillary Thyroid ◽  
Review Of Literature ◽  
Follicular Variant ◽  
Worse Prognosis

AbstractSolid, encapsulated, follicular variant of papillary carcinoma of thyroid is termed as Lindsay tumor. Follicular carcinoma carries a worse prognosis than papillary thyroid carcinoma with higher incidence of hematogenous metastasis. Lindsay tumor being encapsulated follows an indolent course and has a better outcome. We present a rare case of Lindsay tumor in a 30 years adult male who presented with hoarseness of voice.

CD10 Expression is Useful in the Diagnosis of Follicular Carcinoma and Follicular Variant of Papillary Thyroid Carcinoma

Thyroid ◽  
2003 ◽  
Vol 13 (3) ◽  
pp. 291-295 ◽  
Author(s):  
Chisato Tomoda ◽  
Ryoji Kushima ◽  
Eiji Takeuti ◽  
Ken-ichi Mukaisho ◽  
Takanori Hattori ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Follicular Carcinoma ◽  
Papillary Thyroid ◽  
Follicular Variant ◽  
Cd10 Expression

scholarly journals Galectin-3 Immunohistochemical Expression in Thyroid Neoplasms – A Study from Kalaburagi, Karnataka

2021 ◽  
Vol 8 (26) ◽  
pp. 2288-2293
Author(s):  
Anuradha G. Patil ◽  
Saniya Jahan ◽  
Syed Mukhtar Mohiuddin
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Follicular Carcinoma ◽  
Thyroid Neoplasms ◽  
Malignant Neoplasms ◽  
Benign Neoplasms ◽  
Papillary Thyroid ◽  
Follicular Variant ◽  
Galectin 3 ◽  
Malignant Thyroid Neoplasms

BACKGROUND Thyroid carcinoma is the most common endocrine malignancy. Galectin-3 has been implicated in malignant transformation and metastasis of cancer cells and it has received notable recognition for its usefulness as a diagnostic marker for thyroid cancer. We wanted to evaluate the expression of Galectin-3 on thyroid neoplasms, establish its diagnostic accuracy and also differentiate between benign and malignant thyroid lesions. METHODS A total of 54 thyroidectomy specimens were studied over a period of 3 years (2016 - 2019) which included 20 benign and 34 malignant thyroid neoplasms. Histopathologic evaluation of H & E stained sections was done and immunohistochemistry (IHC) staining for Galectin-3 was performed for all neoplasms with the polymeric method using lyophilized mouse monoclonal antibody. (Path n Situ) and grading based on intensity of Galectin-3 expression were noted. RESULTS Galectin-3 expression was significantly higher (P < 0.001) in malignant thyroid neoplasms in comparison to the benign neoplasms. Galectin-3 expression for malignant neoplasms showed sensitivity of 88.23 %, specificity of 95.0 %, positive predictive value (PPV) of 96.8 % and negative predictive value (NPV) of 82.6 %. Galectin-3 expression in Papillary thyroid carcinoma showed a sensitivity of 95.83 % and PPV of 88.2 %. While comparing the neoplasms showing follicular pattern, Galectin-3 expression was more in the malignant neoplasms (follicular carcinoma and follicular variant of papillary carcinoma thyroid) than benign neoplasms (follicular adenoma). CONCLUSIONS Galectin-3 is a useful marker in differentiating benign and malignant thyroid neoplasms. Galectin-3 is sensitive for Papillary thyroid carcinoma (PTC) and among the follicular patterned lesions, Galectin-3 is sensitive for follicular variant of papillary carcinoma and follicular carcinoma. Thus Galectin-3 protein expression evaluated using immunohistochemistry technique acts as an adjunctive ancillary technique in thyroid cancer diagnosis. KEYWORDS Galectin-3, Immunohistochemistry, Thyroid Carcinoma, Papillary Thyroid Carcinoma

Sign in / Sign up

Export Citation Format

Share Document